Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - adrenaline (epinephrine) acid tartrate, quantity: 1.82 mg/ml (equivalent: adrenaline (epinephrine), qty 1 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; hydrochloric acid; sodium hydroxide; water for injections - indications as at 27 june 2003: adrenaline 1:1,000 is the drug of choice in the emergency treatment of acute severe anaphylactic reactions due to insect bites, drugs and other allergens. it may also be used for the symptomatic relief of respiratory distress due to bronchospasm.

Ireland - English - HPRA (Health Products Regulatory Authority)

nod apiary ireland limited - formic acid - bee-hive strip - 68.2 gram(s)/strip - formic acid

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - threonine, quantity: 3.7 mg/ml; proline, quantity: 3 mg/ml; glycine, quantity: 4 mg/ml; arginine, quantity: 8.4 mg/ml; tyrosine, quantity: 0.45 mg/ml; valine, quantity: 7.6 mg/ml; leucine, quantity: 10 mg/ml; serine, quantity: 4 mg/ml; isoleucine, quantity: 6.7 mg/ml; cysteine, quantity: 1.89 mg/ml; taurine, quantity: 0.6 mg/ml; lysine, quantity: 11 mg/ml; ornithine monohydrochloride, quantity: 3.18 mg/ml; histidine, quantity: 3.8 mg/ml; alanine, quantity: 8 mg/ml; aspartic acid, quantity: 6 mg/ml; methionine, quantity: 2.4 mg/ml; glutamic acid, quantity: 10 mg/ml; tryptophan, quantity: 2 mg/ml; phenylalanine, quantity: 4.2 mg/ml - injection, intravenous infusion - excipient ingredients: malic acid; water for injections - primene 10% amino acid iv infusion is indicated in infants and neonates at term or premature, for short-term use, of normal or low birth-weight when oral or enteral nutrition is impossible, insufficient or contraindicated. it is used as an amino acid component in a composite admixture of total parenteral nutrition.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; tryptophan, quantity: 1.9 g/l; methionine, quantity: 5.6 g/l; isoleucine, quantity: 5.6 g/l; serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; arginine, quantity: 11.3 g/l; threonine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - folic acid, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 01 jan 1991 : for the treatment of megaloblastic anaemia, where this has been shown to be due to folic acid deficiency either due to inadequate dietary intake, malabsorption or increased utilisation, including pregnancy and lactation, haemolytic anaemia, hyperthyroidism, exfoliative dermatitis and chronic infection, for prophylaxis during pregnancy and lactation.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - zoledronic acid as monohydrate - concentrate for solution for infusion - zoledronic acid as monohydrate 4 mg - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.

Israel - English - Ministry of Health

taro international ltd, israel - zoledronic acid - concentrate for solution for infusion - zoledronic acid 4 mg / 5 ml - zoledronic acid - treatment of hypercalcaemia of malignancy.treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.prostate cancer should have progressed after treatment with at least one hormonal therapy.

Israel - English - Ministry of Health

rekah pharmaceutical industry ltd, israel - folic acid - tablets - folic acid 5 mg - folic acid - for the treatment of megaloblastic anemias caused by folic acid deficiency.